0R1D.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0R1D.L in your mock portfolio yet.
Sangamo Therapeutics is currently unprofitable, as reflected by its negative EPS and PE ratio. The magnitude of losses implied by EPS of -1.21 and a PE of -0.30 suggests the market is heavily discounting its earnings power and future prospects. Without clear evidence of improving margins or a path to profitability, the financial profile remains weak.
The stock’s current price of $0.37, combined with a 16.8% decline over the last month, indicates strong recent downside momentum. Trading well below the 200-day moving average of $0.81 shows a firmly entrenched longer-term downtrend. An RSI of 41.93 is weak but not yet oversold, suggesting bearish pressure may not be fully exhausted.
Alternative data points show limited growth or even contraction in key indicators that often correlate with business momentum. Web traffic at an estimated 17,054 monthly visitors is modest and not clearly expanding, while job openings have fallen to zero, which can signal cost-cutting or stalled expansion. Social media followership is relatively stable with only marginal changes, suggesting muted external engagement and brand momentum.
Across financials, technicals, and alternative data, Sangamo Therapeutics currently presents a bearish profile. Persistent losses, a deeply discounted share price relative to its 200-day moving average, and weak hiring and engagement signals all point to elevated risk and limited near-term catalysts. Unless there is a clear clinical, partnership, or funding breakthrough, the stock appears vulnerable to continued pressure.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: